Vanguard Group Inc. Purchases 365,581 Shares of Edwards Lifesciences Corporation $EW

Vanguard Group Inc. boosted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 70,363,210 shares of the medical research company’s stock after purchasing an additional 365,581 shares during the period. Vanguard Group Inc. owned about 0.12% of Edwards Lifesciences worth $5,472,147,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Tobam increased its holdings in Edwards Lifesciences by 49.2% during the 3rd quarter. Tobam now owns 67,056 shares of the medical research company’s stock valued at $5,215,000 after purchasing an additional 22,124 shares in the last quarter. Fifth Third Bancorp boosted its stake in Edwards Lifesciences by 6.0% in the third quarter. Fifth Third Bancorp now owns 25,307 shares of the medical research company’s stock worth $1,968,000 after purchasing an additional 1,437 shares in the last quarter. State of New Jersey Common Pension Fund D grew its holdings in shares of Edwards Lifesciences by 2.6% during the third quarter. State of New Jersey Common Pension Fund D now owns 204,069 shares of the medical research company’s stock worth $15,870,000 after purchasing an additional 5,227 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of Edwards Lifesciences by 20.7% in the third quarter. HighTower Advisors LLC now owns 134,112 shares of the medical research company’s stock valued at $10,430,000 after buying an additional 22,977 shares in the last quarter. Finally, GF Fund Management CO. LTD. raised its holdings in shares of Edwards Lifesciences by 20.3% in the third quarter. GF Fund Management CO. LTD. now owns 16,218 shares of the medical research company’s stock valued at $1,261,000 after buying an additional 2,735 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president owned 38,970 shares of the company’s stock, valued at $3,264,127.20. The trade was a 22.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,804 shares of company stock valued at $3,699,082 in the last 90 days. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on EW. Evercore reissued an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 5th. Sanford C. Bernstein reiterated a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Piper Sandler reissued an “overweight” rating and issued a $100.00 price target (up previously from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Finally, Robert W. Baird set a $90.00 price objective on Edwards Lifesciences in a research report on Monday, January 12th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Stock Up 3.3%

Shares of Edwards Lifesciences stock opened at $78.39 on Wednesday. The business has a fifty day simple moving average of $83.07 and a 200 day simple moving average of $81.05. The stock has a market cap of $45.49 billion, a PE ratio of 42.84, a price-to-earnings-growth ratio of 1.99 and a beta of 0.94. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the business posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.